Depression in HIV Infected Patients: a Review

Nanni, Maria Giulia; Caruso, Rosangela; Mitchell, Alex J.; Meggiolaro, Elena; Grassi, Luigi

doi:10.1007/s11920-014-0530-4

Cited by 370 publications

(307 citation statements)

References 113 publications

Supporting

Mentioning

281

Contrasting

Unclassified

Order By: Relevance

“…While we had sufficient statistical power to test our main hypotheses, future studies with larger sample sizes are needed to examine these associations within and between relevant groups, such as sex. For example, consistent with findings from past studies (Arseniou, Arvaniti, & Samakouri, 2014; Nanni, Caruso, Mitchell, Meggiolaro, & Grassi, 2015), we found that women had significantly higher levels of depression when compared to men. We also found differences between men and women in the severity of markers for metabolic disturbances.…”

Section: Discussionsupporting

confidence: 92%

Psychosocial complications of HIV/AIDS-metabolic disorder comorbidities among patients in a rural area of southeastern United States

Hernandez

Kalichman

et al. 2018

J Behav Med

View full text Add to dashboard Cite

As people living with HIV (PLWH) experience longer life-expectancies resulting from antiretroviral therapy, comorbid conditions are increasing, particularly metabolic disorders. There is potential for psychosocial factors such as stigma experiences, depression, and alcohol use to complicate both HIV infection and metabolic disorders, including diabetes mellitus and hyperlipidemia. While the impact of these psychosocial factors on HIV infection alone are widely studied, their role in potentially complicating HIV co-morbid metabolic conditions has received little attention. This study examined the association between HIV-related stigma and depression, and the potential role of alcohol use as a mediating factor in a clinical sample of patients with comorbid HIV infection and metabolic conditions. Results demonstrated that HIV stigma is associated with depression and this relationship is in part accounted for by alcohol use. Our results indicate that interventions aiming to improve the health of people living with HIV and co-morbid metabolic disorders should prioritize addressing alcohol use as it is related to sources of stress, such as stigma, and depression.

show abstract

Section: Discussionsupporting

confidence: 92%

Psychosocial complications of HIV/AIDS-metabolic disorder comorbidities among patients in a rural area of southeastern United States

Hernandez

Kalichman

et al. 2018

J Behav Med

View full text Add to dashboard Cite

show abstract

“…Although causal inferences cannot be made, our results suggest that an effective clinical management of psychological symptoms, particularly of depression and anxiety, may improve the functioning and well-being of both co-infected and mono-infected patients. The recognition and effective management of these symptoms are relevant concerns largely because of the negative effects of such symptoms on cART adherence and persistence (Gonzalez et al, 2011;Schönnesson et al, 2007;Springer et al, 2012) and the possible worsening of disease progression (Nanni et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Assessment of factors associated with the quality of life of patients living with HIV/HCV co-infection

Pereira

Fialho

2016

J Behav Med

View full text Add to dashboard Cite

This study compared the quality of life (QoL) of HIV-infected patients with and without hepatitis C and examined the sociodemographic, HIV-related and psychological symptoms associated with the QoL domains in patients with HIV/HCV co-infection. The sample consisted of 248 HIV/HCV coinfected patients (18-74 years, 81.5% male) and 482 patients only with HIV (24-78 years, 62.7% male). Participants completed the WHOQOL-HIV-Bref questionnaire and the Brief Symptom Inventory (BSI). The HIV/HCV co-infected patients reported significantly lower QoL in all domains, as well as significantly lower scores in 10 of the 17 specific facets. Overall, among the co-infected patients, male gender, employment, combination antiretroviral therapy use and fewer depressive and anxiety symptoms were significantly associated with higher QoL. Symptoms of psychological distress accounted for significant variability in the QoL scores of co-infected patients. These data reinforce the need for tailored interventions to improve the overall well-being of HIV/HCV co-infected patients.

show abstract

“…Healthy General population 10.3% (Kessler et al, 1994) Autoimmune diseases Multiple sclerosis 23.7-50% (Marrie et al, 2015;Siegert and Abernethy, 2005) Systemic lupus 10.8-44% (Ainiala et al, 2001;Nery et al, 2007) Rheumatoid Arthritis 13-48% (Dickens et al, 2002;Matcham et al, 2014) Neurodegenerative disorders Alzheimer's disease 30-50% (Lee and Lyketsos, 2003;Zhao et al, 2016) Parkinson's disease 7-76% (Veazey et al, 2005;Bomasang-Layno et al, 2015 ) Huntington's disease 48.2% (Wetzel et al, 2011) Metabolic disorders Obesity 20-55% (Luppino et al, 2010;Stunkard et al, 2003) Cardiovascular diseases 17-27% (Rudisch and Nemeroff, 2003;Seligman and Nemeroff, 2015) Type 2 diabetes 12.8-26% (Ali et al, 2006;Anderson et al, 2001) Infection/environmental diseases Chronic obstructive pulmonary disorders 6-42% (Maurer et al, 2008) HIV 5-42% (Cruess et al, 2003;Nanni et al, 2015) Asthma 7.6-20.2% (Jiang et al, 2014) This table was adapted from Iwata et al (2013) and updated to include recent clinical findings. (Black and Miller, 2015;Fornaro et al, 2013;Hernandez et al, 2008;Huang and Lee, 2007;Leo et al, 2006;Liu et al, 2004;Maes et al, 1993;Owen et al, 2001;Simon et al, 2008) IL-1RA ↑ ↑ or ↓ (Liu et al, 2004;Maes et al, 1997;Tsai et al, 2012) IL-2 ↑ or -- (Fornaro et al, 2013;Hernandez et al, 2008;…”

Section: Table 1: Co-morbidity Of Mdd With Inflammatory Diseasesmentioning

confidence: 99%

Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience

Ménard

Pfau

Hodes

et al. 2016

Neuropsychopharmacol

264

201

View full text Add to dashboard Cite

Diagnostic criteria for mood disorders including major depressive disorder (MDD) largely ignore biological factors in favor of behavioral symptoms. Compounding this paucity of psychiatric biomarkers is a need for therapeutics to adequately treat the 30-50% of MDD patients who are unresponsive to traditional antidepressant medications. Interestingly, MDD is highly prevalent in patients suffering from chronic inflammatory conditions, and MDD patients exhibit higher levels of circulating pro-inflammatory cytokines. Together, these clinical findings suggest a role for the immune system in vulnerability to stress-related psychiatric illness. A growing body of literature also implicates the immune system in stress resilience and coping. In this review, we discuss the mechanisms by which peripheral and central immune cells act on the brain to affect stress-related neurobiological and neuroendocrine responses. We specifically focus on the roles of pro-inflammatory cytokine signaling, peripheral monocyte infiltration, microglial activation, and hypothalamic-pituitary-adrenal axis hyperactivity in stress vulnerability. We also highlight recent evidence suggesting that adaptive immune responses and treatment with immune modulators (exogenous glucocorticoids, humanized antibodies against cytokines) may decrease depressive symptoms and thus represent an attractive alternative to the current antidepressant treatments.

show abstract

Depression in HIV Infected Patients: a Review

Cited by 370 publications

References 113 publications

Psychosocial complications of HIV/AIDS-metabolic disorder comorbidities among patients in a rural area of southeastern United States

Psychosocial complications of HIV/AIDS-metabolic disorder comorbidities among patients in a rural area of southeastern United States

Assessment of factors associated with the quality of life of patients living with HIV/HCV co-infection

Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience

Contact Info

Product

Resources

About